387 related articles for article (PubMed ID: 23159463)
1. Genetic sequence variants are associated with severity of lower urinary tract symptoms and prostate cancer susceptibility.
Helfand BT; Hu Q; Loeb S; McVary KT; Catalona WJ
J Urol; 2013 Mar; 189(3):845-8. PubMed ID: 23159463
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
3. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
[TBL] [Abstract][Full Text] [Related]
4. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems.
Parsons JK
J Urol; 2007 Aug; 178(2):395-401. PubMed ID: 17561143
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
Huang SP; Huang LC; Ting WC; Chen LM; Chang TY; Lu TL; Lan YH; Liu CC; Yang WH; Lee HZ; Hsieh CJ; Bao BY
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3068-74. PubMed ID: 19900942
[TBL] [Abstract][Full Text] [Related]
6. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.
Fukuta F; Masumori N; Mori M; Tsukamoto T
Int J Urol; 2013 Jan; 20(1):100-6. PubMed ID: 23106204
[TBL] [Abstract][Full Text] [Related]
8. Can noninvasive evaluation of benign prostatic obstruction be optimized?
Løvvik A; Yaqub S; Oustad H; Sand TE; Nitti VW
Curr Opin Urol; 2012 Jan; 22(1):1-6. PubMed ID: 22080874
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer.
Sierra Díaz E; Sánchez Corona J; Rosales Gómez RC; Gutierrez Rubio SA; Vázquez Camacho JG; Solano Moreno H; Morán Moguel MC
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):241-6. PubMed ID: 20026870
[TBL] [Abstract][Full Text] [Related]
10. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
[TBL] [Abstract][Full Text] [Related]
11. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
12. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men.
Corica FA; Jacobsen SJ; King BF; Bostwick DG; Jacobson DJ; Girman CJ; Lieber MM
J Urol; 1999 Mar; 161(3):831-4. PubMed ID: 10022695
[TBL] [Abstract][Full Text] [Related]
13. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.
Fujimura T; Kume H; Nishimatsu H; Sugihara T; Nomiya A; Tsurumaki Y; Miyazaki H; Suzuki M; Fukuhara H; Enomoto Y; Homma Y
BJU Int; 2012 May; 109(10):1512-6. PubMed ID: 21883834
[TBL] [Abstract][Full Text] [Related]
14. Evaluation and treatment of lower urinary tract symptoms in older men.
Abrams P; Chapple C; Khoury S; Roehrborn C; de la Rosette J;
J Urol; 2013 Jan; 189(1 Suppl):S93-S101. PubMed ID: 23234640
[TBL] [Abstract][Full Text] [Related]
15. Benign prostatic hyperplasia: clinical manifestations and evaluation.
Santos Dias J
Tech Vasc Interv Radiol; 2012 Dec; 15(4):265-9. PubMed ID: 23244722
[TBL] [Abstract][Full Text] [Related]
16. Incidence rates and risk factors for acute urinary retention: the health professionals followup study.
Meigs JB; Barry MJ; Giovannucci E; Rimm EB; Stampfer MJ; Kawachi I
J Urol; 1999 Aug; 162(2):376-82. PubMed ID: 10411042
[TBL] [Abstract][Full Text] [Related]
17. Are polymorphisms of the β(3)-adrenoceptor gene associated with an altered bladder function?
Teitsma CA; de la Rosette JJ; Michel MC
Neurourol Urodyn; 2013 Mar; 32(3):276-80. PubMed ID: 22972489
[TBL] [Abstract][Full Text] [Related]
18. Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention.
Nickel JC; Roehrborn CG; Castro-Santamaria R; Freedland SJ; Moreira DM
J Urol; 2016 Nov; 196(5):1493-1498. PubMed ID: 27378134
[TBL] [Abstract][Full Text] [Related]
19. Association of chromosomal locus 8q24 and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy.
Meyer A; Schürmann P; Ghahremani M; Kocak E; Brinkhaus MJ; Bremer M; Karstens JH; Hagemann J; Machtens S; Dörk T
Urol Oncol; 2009; 27(4):373-6. PubMed ID: 18625567
[TBL] [Abstract][Full Text] [Related]
20. Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.
Oh JJ; Byun SS; Lee SE; Hong SK; Jeong CW; Kim D; Kim HJ; Myung SC
Gene; 2014 Jan; 533(1):86-93. PubMed ID: 24120391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
